Targeted Therapies To Restore Heart Function

We develop therapeutics to directly target the heart, using an authentic human cardiac organoid discovery engine.

Targeted Therapies To Restore Heart Function

Overcoming the Innovation Gap

Heart failure affects 4% of the US population, yet treatment options are primarily symptomatic, including blood thinners, assistive devices and heart transplant. Patients today face a 50% 5-year survival rate upon diagnosis.

Our approach is to engineer human cardiac organoids that function similarly to adult human heart tissue, enabling us to directly target therapeutics to the heart. 

We aim to address the root cause of heart failure and restore heart function.

Our Cardiovascular Discovery Engine

We’ve developed HeartDyno, our cardiac organoid discovery engine, using scalable, authentic and predictive cardiac organoids that reflect adult heart phenotype, toxicology, and physiological function. HeartDyno combines these with a deep multi-omics data approach, uncovering novel therapeutic targets and candidates that offer better efficacy and safety profiles in humans.


Engineered from stem cells at scale


Mature phenotype and physiology


Translates to clinical observation

News & Views

March, 2021

Research identifies cause and potential treatment for COVID-19-induced heart damage

QIMR Berghofer researchers in collaboration with Dynomics and Resverlogix have discovered some of the ways COVID-19 damages the heart, and identified a class of drugs that could potentially protect or reverse this cardiac injury.

April, 2020

The state of the art in cardiac organoids

Structural and functional changes following infarction in a human heart can be modeled with human cardiac organoids set in hypoxic gradient and stimulated with the neurotransmitter noradrenaline.

March, 2019

Thousands of tiny hearts grown in lab to test new drugs

When it comes to determining whether new drugs will be effective, our team looked to mini beating human hearts. Thousands of them.

Publication Highlights

Inflammatory Cardiac Dysfunction

🔥 NEW! Mills, R. J. et al. BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection. Cell, Online Now, 10.1016/j.cell.2021.03.026 (2021).

🔥 NEW! Robson, A, Preventing cardiac damage in patients with COVID-19. Nature Reviews Cardiology, Online Now, 10.1016/j.cell.2021.03.026 (2021).

HeartDyno Human Cardiac Organoid Platform

Cardiac Regeneration and Gene Profiling

🔥 NEW! Sim Choon Boon et al. Sex-Specific Control of Human Heart Maturation by the Progesterone Receptor. Circulation (2021).

Quaife-Ryan, G. A. et al. β-Catenin drives distinct transcriptional networks in proliferative and nonproliferative cardiomyocytes. Development 147, (2020).

Quaife-Ryan G. A. et al. Multicellular Transcriptional Analysis of Mammalian Heart Regeneration. Circulation 136, 1123–1139 (2017).

Porrello, E. R. et al. Transient Regenerative Potential of the Neonatal Mouse Heart. Science 331, 1078–1080 (2011).


    Targeted therapies to restore heart function.



    News & Views



    Follow Us